Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
8:01 am ET April 15, 2020 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") announced today the successful results of a Phase 1b clinical study of iCo's Oral Amphotericen B Delivery System ("Amp B" or "iCo 019") which began on December 9, 2019. The purpose of the study was to evaluate the safety, tolerability and pharmacokinetics of 100mg and 400mg doses of iCo 019.
iCo also announced the appointment of Dr. Kishor Wasan as Director of Research for the Company. Dr. Wasan has received numerous awards for his contributions to health sciences including the Canadian Society of Pharmaceutical Sciences Leadership award for outstanding contributions to Pharmaceutical Sciences in Canada and is a Fellow of the Canadian Academy of Health Sciences and the American Association of Pharmaceutical Scientists. Dr. Wasan has published over 240 peer-reviewed articles and 280 abstracts in the area of lipid-based drug delivery and lipoprotein-drug interactions. Most recently, Dr. Wasan served as the Dean of the College of Pharmacy and Nutrition of the University of Saskatchewan from August 2014 to June 2019. Dr. Wasan led the research team at the Wasan lab at the University of British Columbia that developed what has become iCo 019, and will initially focus his efforts on the further development of iCo 019 via partnerships and collaborations. "We are delighted to have Kish formally onboard leading our research efforts. We've worked with him since the founding of the Company and will benefit from his proven research abilities and deep connectivity to the global pharmaceutical industry," noted William Jarosz, the CEO of iCo.
Commenting on the iCo 019 trial Dr. Wasan noted, "In the Phase Ib human clinical study all repeated doses of ICO-019 were well tolerated with no serious adverse events including no signs of GI, kidney or liver toxicities. ICO-019 at the 100 mg dose achieved a median plasma Cmax of 25 ng AmB/mL and AUC (0-inf) 990 hr* ng/mL after day 1 of dosing and a median plasma Cmax of 44 ng AmB/mL and AUC (0-inf) 1998 hr*ng/mL after 10 day of dosing. This approximate doubling of the AUC (0-inf) measure between day 1 and day 10 was observed not only at the 100 mg dose but at the 400 mg dose as well.
These data suggest that we may have developed a novel oral amphotericin B formulation that is safe and tolerable following multiple dosing to healthy human subjects. In addition, the increased AUC observed in the phase 1b human clinical studies between the day 1 of dosing to the day 10 of dosing suggests that iCO-19 formulation has the ability to increase and sustain Amphotericin B tissue concentrations within infected tissues without the associated GI, liver or kidney toxicity. I am pleased with the PK results from the Phase 1b trial."
In addition, iCo announced it will delay the start of the anticipated Phase 2 trial of iCo 019 as the result of uncertainty generated by the current COVID-19 events. "We are concerned that the ongoing pandemic could cause clinical challenges affecting our trial's timeline, leading to longer than expected delays and higher costs. Despite the positive findings of our Phase 1b trial, we believe it is the best use of our resources, and the resouces of our clinical research partners in the current environment, to delay the start of the Phase 2 trial until we have more clarity regarding the course of COVID-19 and its effect on clinical trial practices," stated Mr Jarosz.
most of us lost big on this scam...but if you have any money left to invest I have bought ICOTF which owns the license to Bertilimumab which now Alexion Pharmaceuticals took over for IMNP and must pay ICOTF $32m milestone payment to take Bert to PH3... which means that ICOTF's cap rate should go to 10x since it is at $3m now and selling at .02c a share...just a suggestion if you would like to benefit from Bertilimumab since IMNP dropped the ball and couldn't get it done...good luck to you anyway
Alexion is obligated to pay them $32m to move Bert to ph3...a 10x move on their current market cap to about 20c per share plus
yes sir
iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up
8:02 am ET February 10, 2020 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in its Phase 1b study have received doses of Oral Amphotericin B (either 100mg and 400mg/day) over ten days and, subsequent to dosing, have been followed up for an additional ten days. Full results of the Phase 1b study are currently expected before the end of Q1 2020.
Stated Dr. Peter Hnik, Chief Medical Officer of iCo, "Results from the Phase 1b study using multiple ascending doses of oral Amphotericin B will provide additional safety and pharmacokinetic information needed for the upcoming Phase 2 clinical study in patients with vulvovaginal candidiasis ("VVC").
According to Denning et al, "Worldwide, recurrent vulvovaginal candidiasis affects about 138 million women annually (range 103-172 million), with a global annual prevalence of 3871 per 100?000 women; 372 million women are affected by recurrent vulvovaginal candidiasis over their lifetime. The 25-34 year age group has the highest prevalence (9%). By 2030, the population of women with recurrent vulvovaginal candidiasis each year is estimated to increase to almost 158 million, resulting in 20,240,664 extra cases with current trends using base case estimates in parallel with an estimated growth in females from 3·34 billion to 4·181 billion. In high-income countries, the economic burden from lost productivity could be up to US$14·39 billion annually."*
A Phase 2 study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis is currently expected to commence in Q2 2020.
A number of additional indications, that may also be difficult and impractical to treat using intravenous formulation, are expected to be explored (active treatment and prevention) in the near future.
iCo also announces that the Company has also engaged Proconsul Capital ("Proconsul") for investor relations activities. Proconsul will be paid $8,000 CDN, excluding taxes, on a month-to-month basis.
from Alexion website:
Immune Pharma - anti-eotaxin-1 antibody
Phase: Preclinical
In November 2019, Alexion acquired an anti-eotaxin-1 antibody from Immune Pharma for potential development in inflammatory diseases.
some folks on the IMNP chat room still believe that Bert has not been transferred to Alexion...dummies
I like real meat...
they were chasing some shares on Tuesday the last trading day of the year but quiet today starting out in 2020...but yes this one should do well with Alexion as the new partner to develop Bertilimumab that IMNP dropped the ball on it.
the point is that I got burned on this stock with this false narrative and delusional posts...Bert has been transferred to Alexion and all that is left in this chapt 11 shit show is Ceplene which nobody wants and that Amiket bullshit cream that you can wipe your ass with...
IMNP says goodbye to Bertilimumab...
iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
8:03 am ET December 24, 2019 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - December 24, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received 100 mg doses of Oral Amphotericin B on a daily basis over ten days, with no drug-related adverse events observed to date. One additional cohort is expected to be dosed in early Q1 2020, followed by the initiation of a Phase II study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis in Q2 2020.
iCo also announces the completion of the transfer of its sub-license of iCo-008, an antibody targeting eotaxin-1, with the receipt of an assignment and assumption acknowledgement from its new biotechnology partner with a market capitalization in excess of $24 billion USD. Furthermore, iCo has communicated to its pharmaceutical partner, which previously licensed iCo-008 worldwide exclusive to iCo, the completion of said sub-license transfer in its annual report.
iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
8:03 am ET December 24, 2019 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - December 24, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received 100 mg doses of Oral Amphotericin B on a daily basis over ten days, with no drug-related adverse events observed to date. One additional cohort is expected to be dosed in early Q1 2020, followed by the initiation of a Phase II study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis in Q2 2020.
iCo also announces the completion of the transfer of its sub-license of iCo-008, an antibody targeting eotaxin-1, with the receipt of an assignment and assumption acknowledgement from its new biotechnology partner with a market capitalization in excess of $24 billion USD. Furthermore, iCo has communicated to its pharmaceutical partner, which previously licensed iCo-008 worldwide exclusive to iCo, the completion of said sub-license transfer in its annual report.
Phase 2 Bertilimumab Trial
On May 15, 2018 our licensee announced positive Phase 2 data for the treatment of moderate-to-extensive bullous pemphigoid. iCo Therapeutics is eligible to receive up to $32M in potential future milestone payments. For more information please refer to:
www.immunepharma.com/immune-pharmaceuticals-presents-updated-positive-results-from-phase-2-trial-of-bertilimumab-in-bullous-pemphigoid/
ALEXION PHARMACEUTICALS TOOK OVER THIS LICENSE FROM IMNP BANKRUPTCY
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced it has engaged Ora, Inc., the world's leading full-service ophthalmic CRO and product development firm, to assist the Company with its ophthalmic regulatory and development strategy for iCo-008. It is expected that this work will ultimately result in a meeting with the FDA prior to initiation of a Phase 2 trial. Ora has vast expertise in ocular allergy and immunology, both pre-clinical and clinical, and has been involved in multiple drug approvals in this area. Paul Gomes, Vice President of Allergy and Blepharitis at Ora, commented, "We are very excited to collaborate with iCo in engaging with the FDA to establish a development pathway for iCo-008 for severe ocular allergic diseases. In the US, there have been no new therapies approved for these orphan diseases within the last 25 years. Innovation is necessary to increase the available treatment options and to reduce or eliminate the need for chronic steroid usage. "
Previously iCo announced the conclusion of court proceedings in the US and Israel, resulting in approval of Alexion's asset purchase agreement related to iCo-008, an anti-eotaxin-1 antibody. iCo retains worldwide ophthalmic use indications, including Vernal Keratoconjunctivitis (VKC) and Atopic Keratoconjunctivitis (AKC).
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received the first dose of Oral Amphotericin B. Dosing will occur over a period of ten days. One additional cohort is expected to be dosed in Q1 2020, followed by the initiation of a Phase II study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis in Q2 2020.
All subjects in the Phase 1b study will be dosed for 10 consecutive days with additional 10 days of follow-up (for a total of 20 days). Two doses of oral Amphotericin B (100mg and 400mg), showing promising pharmacokinetic outcomes in the previous Phase 1 trial (using a single dose only), will be used in the Phase 1b study. Extensive safety and pharmacokinetic testing will also be performed throughout the study to indicate which dose might be the safest and effective for future trials in patients with fungal diseases.
you are reading some kind of exception to sale of the rights of IMNP to Alexion...keep dreaming Bertilimumab is gone and your money is gone with it...all that is left is Ceplene which nobody wants except Teper who doesn't seem to be able to raise enough money to fund his lunch at Mcdonalds
it's going to take time with Ico like you said but Alexion will be taking over Bertilimumab for sure..and instead of paying Ico $32m in milestone payments for ph 3 and 8% royalties. Alexion should consider buying Ico would be the smart thing to do with a cap of $7m now...just my thinking
IMNP sold their license rights to Bertilimumab to Alexion with court approval and now those rights accrue back to Ico who sub licensed it to IMNP and is all relevant to this board...and the fact that you are saying otherwise is not a lie because you actually believe it... so either you are insane or just dumb.
Alexion is required to pay ICo $32m milestone payment is they take Bertilimumab to PH 3 on Bullous Pemphigoid or UC and then 8% royalties on sales...that should push the stock up with a cap rate of less than $7.5m now at 5c a share
good luck pushing for IMNP was in it for years just like you...thought some might want to pursue Bertilimumab thru ICO since IMNP doesn't own it any more.
I am still here to inform anyone that was in IMNP because of Bertilimumab as I was and to buy ICOTF that licensed Bertilimumab to Alexion after the rights were sold to Alexion in the IMNP bankruptcy and to benefit from the milestone payments to ICOTF from Alexion to develop Bertilimumab...
...already sold all my shares when Bert went to Alexion, nothing left at IMNP but the bad memories of all the deception and crooked dealings by mgmt
the article below is why I bought some ICOTF shares to try and recoup some of the money I lost on IMNP shares thru the marketing of Bertilimumab by Alexion
(ICO.V) Alexion Pharmaceuticals - iCo's New Partner for the Development and Commercialization of iCo-008
Nov. 25, 2019 8:08 am ET
Order Reprints
Print Article
Text size
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced today that the purchase of the assets of Immune Pharmaceuticals ("Immune"), including the sublicense of iCo-008, by Alexion Pharmaceuticals, Inc. ("Alexion") has received all requisite court approvals and the closing of the purchase transaction is expected prior to the end of Q1 2020. Alexion has assumed Immune's rights and obligations under the iCo/Immune sublicense agreement in consideration of a USD $6 million (CDN $8 million) payment in accordance with the bankruptcy proceedings of Immune.
"Alexion, one of the top 15 biotechnology companies in the world by market capitalization, is a world leader in the development of therapeutics for orphan indications and we are pleased that after significant diligence they have elected to further develop iCo's anti-eotaxin antibody for significant unmet medical conditions", stated Andrew Rae, President and CEO of iCo Therapeutics.
The obligations assumed by Alexion under the iCo sub-license with Immune include milestone payments of up to $32M USD and royalties on sales of Bertilimumab, also known as iCo-008, an antibody targeting eotaxin-1. Upon closing the purchase transaction Alexion has rights to develop and commercialize iCo-008 for non-ophthalmic indications worldwide, pursuant to the terms of the sublicense, while iCo continues to retain worldwide ophthalmic use indications and is in the planning stages for an additional Phase 2 clinical trial. As contemplated by the Sublicense, iCo intends to provide a notice to confirm its consent to the transaction.
Skier is 100% right...the bankruptcy of IMNP gave all its rights under their license agreement for Bertilimumab with ICO to Alexion for $6m.
IMNP has Amiket and Ceplene if you still want to buy their shares but Bertilimumab is gone from IMNP for sure...anyone thinking otherwise is totally wrong.
I have sold all of my IMNP shares...and have bought some ICOTF to try and benefit from the Alexion sub license and payments to ICOTF...Teper, Maza and Fiorino were the liars.
Alexion will perform with Bertilimumab and will pay the milestone payments and royalties to ICOTF...should be good for ICOTF stockholders since IMNP turned out to be scammers and Alexion is a real company
100% true
100% true
Nov 25, 2019 · (ICO.V) Alexion Pharmaceuticals - iCo's New Partner for the Development and Commercialization of iCo-008. ... The obligations assumed by Alexion under the iCo sub-license with Immune include milestone payments of up to $32M USD and royalties on sales of Bertilimumab, also known as iCo-008, an antibody targeting eotaxin-1.
if you want to continue invested in Bert then buy ICOTF because they hold the license for it that was auctioned to Alexion from IMNP bankruptcy...
Alexion has to pay ICOTF $32m when they do a phase 3 on Bert and 8% royalties for any sales...ICOTF has a cap of less than $7.5m now and is selling under .05c
thanks to all the stockholders that fought all the way...no hard feelings
2.8m shares shorted yesterday...wasn't LK
why sell 2.5m shares and why buy 2.5m shares?
2m shares bought with knowing something...thieves
don't they have to say something today?
they probably have not filed any reports because they don't have any money to pay the accountants to do them...
since no one knows what the highest offer is going to be on Sept 16 when the auction starts...let's believe we are going to get a huge offer and if it doesn't happen then we can get pissed off and curse these guys, and sue them, and report them to the SEC and have them banned forever from holding office in a public company again...
these basturds helped bury this stock...would love to see some real hurt on these creeps
would love to see these shorts not able to cover and a big offer come in and they get burned big time